Dr. Stefanie Aeppli
Medizinische Onkologie und Hämatologie · Dept. I
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Cathomas R, Rothschild S, Hayoz S, Bubendorf L, Özdemir B, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel R, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U. Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17. J Clin Oncol 2023; 41:5131-5139.
Aug 17, 2023Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Aug 17, 2023J Clin Oncol 2023; 41:5131-5139
Cathomas Richard, Rothschild Sacha I, Hayoz Stefanie, Bubendorf Lukas, Özdemir Berna C, Kiss Bernhard, Erdmann Andreas, Aeppli Stefanie, Mach Nicolas, Strebel Räto T, Hadaschik Boris, Berthold Dominik R, John Hubert, Zihler Deborah, Schmid Mathias, Alborelli Ilaria, Schneider Martina, Musilova Jana, Spahn Martin, Petrausch Ulf
Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018.
Aeppli S, Engeler D, Fischer S, Omlin A, Pratsinis M, Hermann C, Rothermundt C. Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018. Swiss Med Wkly 2022; 152:w30175.
Jun 16, 2022Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018.
Jun 16, 2022Swiss Med Wkly 2022; 152:w30175
Aeppli Stefanie, Engeler Daniel, Fischer Stefanie, Omlin Aurelius, Pratsinis Manolis, Hermann Christian, Rothermundt Christian
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts
Aeppli S, Rothermundt C, Sternberg C, Schmidinger M, Rini B, Porta C, Oldenburg J, McDermott D, Larkin J, Grünwald V, Escudier B, Eisen T, Schmaus M, Putora P. First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. ESMO Open 2021; 6:100030.
Jan 15, 2021First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts
Jan 15, 2021ESMO Open 2021; 6:100030
Aeppli Stefanie, Rothermundt Christian, Sternberg C N, Schmidinger M, Rini B I, Porta C, Oldenburg J, McDermott D, Larkin J, Grünwald V, Escudier B, Eisen T, Schmaus M, Putora Paul Martin
Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland
Moccia A, Mingrone W, Novak U, Pfleger C, Richter P, Rütti M, Schmidt A, Stenner F, Voegeli M, Zander T, Zucca E, Mey U, Lang N, Aeppli S, Güsewell S, Bargetzi M, Caspar C, Brülisauer D, Ebnöther M, Fehr M, Fischer N, Ghilardi G, Krasniqi F, Hitz F. Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland. Hematol Oncol 2020; 39:196-204.
Dec 23, 2020Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland
Dec 23, 2020Hematol Oncol 2020; 39:196-204
Moccia A A, Mingrone W, Novak U, Pfleger C, Richter P, Rütti M, Schmidt A, Stenner F, Voegeli M, Zander T, Zucca E, Mey U, Lang N, Aeppli Stefanie, Güsewell Sabine, Bargetzi M, Caspar C, Brülisauer D, Ebnöther M, Fehr Martin, Fischer N, Ghilardi G, Krasniqi F, Hitz Felicitas
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma
Aeppli S, Sternberg C, Schmidinger M, Rini B, Porta C, Omlin A, Oldenburg J, McDermott D, Gruenwald V, Larkin J, Fischer S, Escudier B, Eisen T, Eboulet E, Rothermundt C. Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. ESMO Open 2020; 5
Jan 1, 2020Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma
Jan 1, 2020ESMO Open 2020; 5
Aeppli Stefanie, Sternberg Cora, Schmidinger Manuela, Rini Brian, Porta Camillo, Omlin Aurelius, Oldenburg Jan, McDermott David, Gruenwald Viktor, Larkin James, Fischer Stefanie, Escudier Bernard, Eisen Tim, Eboulet Eric Innocents, Rothermundt Christian
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort
Schmid S, Aeppli S, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort. Lung Cancer 2019
Mar 5, 2019Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort
Mar 5, 2019Lung Cancer 2019
Schmid Sabine, Aeppli Stefanie, Früh Martin
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
Schmid S, Jochum W, Demmer I, Foerbs D, Janthur W, Wannesson L, Rothschild S, Pless M, Gautschi O, Britschgi C, Aeppli S, Klingbiel D, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. Lung Cancer 2019; 130:149-155.
Feb 19, 2019Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
Feb 19, 2019Lung Cancer 2019; 130:149-155
Schmid Sabine, Jochum Wolfram, Demmer I, Foerbs D, Janthur W, Wannesson L, Rothschild S, Pless M, Gautschi O, Britschgi C, Aeppli Stefanie, Klingbiel D, Früh Martin
Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumab
Aeppli S, Driessen C, Graf L, Hitz F. Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumab. Hematol Oncol 2018
Aug 3, 2018Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumab
Aug 3, 2018Hematol Oncol 2018
Aeppli Stefanie, Driessen Christoph, Graf Lukas, Hitz Felicitas